Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Adenocarcinoma|HER2 Positive Breast Carcinoma|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7
Interventions: DRUG: Aromatase Inhibition Therapy|DRUG: Cyclophosphamide|DRUG: Doxorubicin Hydrochloride|OTHER: Laboratory Biomarker Analysis|DRUG: Paclitaxel|DRUG: Tamoxifen Citrate|BIOLOGICAL: Trastuzumab
Sponsor: National Cancer Institute (NCI)
Collaborators: Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|Canadian Cancer Trials Group|SWOG Cancer Research Network